These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16856801)

  • 1. Infliximab for the treatment of psoriasis.
    Kleyn CE; Griffiths CE
    Expert Opin Biol Ther; 2006 Aug; 6(8):797-805. PubMed ID: 16856801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab in dermatological treatment: beyond psoriasis.
    Rigopoulos D; Korfitis C; Gregoriou S; Katsambas AD
    Expert Opin Biol Ther; 2008 Jan; 8(1):123-33. PubMed ID: 18081542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab for psoriasis.
    Gottlieb AB
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S112-7. PubMed ID: 12894134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New development in the treatment of psoriasis--infliximab.
    Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of severe refractory psoriasis with infliximab].
    Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Oliver Martínez V; Soriano Navarro CJ; Fortea Baixauli JM
    Med Clin (Barc); 2004 Nov; 123(17):657-8. PubMed ID: 15563800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.
    Gottlieb AB; Masud S; Ramamurthi R; Abdulghani A; Romano P; Chaudhari U; Dooley LT; Fasanmade AA; Wagner CL
    J Am Acad Dermatol; 2003 Jan; 48(1):68-75. PubMed ID: 12522373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the treatment of psoriasis with infliximab.
    Vamvouris T; Hadi S
    Rev Recent Clin Trials; 2006 Sep; 1(3):201-5. PubMed ID: 18473973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
    Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
    Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
    Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab: efficacy in psoriasis.
    Arsiwala S
    Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S25-34. PubMed ID: 23974692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab treatment of psoriasis in supervised infusion centers: case management experience.
    Campos Muñoz L; de Unamuno Bustos B; Herranz Pinto P; El Ahmed HH; Ruiz-Villaverde R; Taberner Ferrer R
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S17-24. PubMed ID: 24777572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
    Winterfield L; Menter A
    Dermatol Clin; 2004 Oct; 22(4):437-47, ix. PubMed ID: 15450339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
    Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
    Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infliximab. Role in the treatment of psoriasis].
    Mössner R; Reich K
    Hautarzt; 2005 Sep; 56(9):831-2, 834-8. PubMed ID: 16133635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.
    Schopf RE; Aust H; Knop J
    J Am Acad Dermatol; 2002 Jun; 46(6):886-91. PubMed ID: 12063486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions.
    Oh CJ; Das KM; Gottlieb AB
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):829-30. PubMed ID: 10775863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
    Newland MR; Weinstein A; Kerdel F
    Int J Dermatol; 2002 Jul; 41(7):449-52. PubMed ID: 12121565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.